Literature DB >> 8582196

Symptoms related to the menopause and sex steroid treatments.

T Bäckström1.   

Abstract

In the menopause transition, ovarian steroid production is gradually inhibited and around 35% of women will seek medical help for postmenopausal symptoms. The hot flush is a characteristic manifestation occurring in about 70% of women; it is associated with oestrogen withdrawal and disappears with oestrogen-based hormone replacement therapy. The exact mechanism behind it is still unclear but is probably related to heat loss mechanisms. The flush often occurs in parallel to changes in skin temperature, blood flow, pulse rate and pulses of luteinizing hormone (LH). These are probably secondary to a disturbance in the thermoregulatory centre of the CNS, which is anatomically close to neurons containing gonadotropin-releasing hormone. Depression is no more frequent in the menopausal transition than at other times in life. After surgical menopause, however, oestrogen improves low mood over placebo. In women with premenstrual syndrome, an increased feeling of well-being is associated with the pre-ovulatory oestrogen peak. Progestogens are associated with negative mood changes during the menstrual cycle, oral contraception and postmenopausal replacement therapy. Certain progesterone metabolites are anaesthetic and have anti-epileptic and anxiolytic properties, effects which are mediated via the type A gamma-aminobutyric acid (GABAA) receptor. Oestrogen is associated with increased sensory perception, locomotory activity, limb coordination and balance: this may help explain the increased frequency of bone fractures in the early postmenopausal period. Oestrogen improves memory and performance in patients with mild Alzheimer's dementia and increases epileptic activity in patients with partial epilepsy. These effects can be related to amplifying effects of oestrogen on excitatory amino acids in the CNS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582196     DOI: 10.1002/9780470514757.ch10

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  6 in total

Review 1.  The menopause and its treatment in perspective.

Authors:  F Al-Azzawi
Journal:  Postgrad Med J       Date:  2001-05       Impact factor: 2.401

2.  Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone.

Authors:  G E Duncan; D J Knapp; S W Carson; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

3.  Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).

Authors:  Wenjie Jessie Lu; Robert Bies; Landry K Kamden; Zeruesenay Desta; David A Flockhart
Journal:  Drug Metab Dispos       Date:  2010-04-21       Impact factor: 3.922

4.  Potential contribution of aromatase inhibition to the effects of nicotine and related compounds on the brain.

Authors:  Anat Biegon; Nelly Alia-Klein; Joanna S Fowler
Journal:  Front Pharmacol       Date:  2012-11-06       Impact factor: 5.810

5.  Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women.

Authors:  Akira Oishi; Yoshiko Mochizuki; Reiko Otsu; Noriyuki Inaba
Journal:  Biopsychosoc Med       Date:  2007-06-05

6.  Luffa cylindrica: a promising herbal treatment in progesterone induced obesity in mice.

Authors:  Wilnoska Wilnellia D'silva; Prakash Rajshekhar Biradar; Ashwini Patil
Journal:  J Diabetes Metab Disord       Date:  2021-02-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.